A pilot study of reduced dose cyclosporine and corticosteroids to reduce new onset diabetes mellitus and acute rejection in kidney transplant recipients

Edward H Cole, G V Ramesh Prasad, Carl J Cardella, Joseph S Kim, Kathryn J Tinckam, Daniel C Cattran, Jeffrey R Schiff, David N Landsberg, Jeffrey S Zaltzman, John S Gill, Edward H Cole, G V Ramesh Prasad, Carl J Cardella, Joseph S Kim, Kathryn J Tinckam, Daniel C Cattran, Jeffrey R Schiff, David N Landsberg, Jeffrey S Zaltzman, John S Gill

Abstract

Background: New onset diabetes mellitus (NODM) and acute rejection (AR) are important causes of morbidity and risk factors for allograft failure after kidney transplantation.

Methods: In this multi-center, open label, single-arm pilot study, 49 adult (≥18 years of age), low immunologic risk, non-diabetic recipients of a first deceased or living donor kidney transplant received early steroid reduction to 5 mg/day combined with Thymoglobulin® (Genzyme Transplant, Cambridge, MA, USA) induction, low dose cyclosporine (2-hour post-dose (C2) target of 600 to 800 ng/ml) and mycophenolic acid (MPA) therapy.

Results: Six months after transplantation, two patients (4%) developed NODM and one patient (2%) developed AR. Four patients had impaired fasting glucose tolerance based on 75-g oral glucose tolerance testing (OGTT). There was one patient death. There were no episodes of cytomegalovirus (CMV) infection or BK virus nephritis. In contrast, in a historical cohort of n = 27 patients treated with Thymoglobulin induction, and conventional doses of cyclosporine and corticosteroids, the incidence of NODM and AR was 18% and 15%.

Conclusions: The pilot study results suggest that Thymoglobulin induction combined with early steroid reduction, reduced cyclosporine exposure and MPA, may reduce the incidence of both NODM and AR in low immunological risk patients. A future controlled study enriched for patients at high risk for NODM is under consideration.

Trial registration: ClinicalTrials.gov: http://NCT00706680.

References

    1. Schold JD, Santos A, Rehman S, Magliocca J, Meier-Kriesche HU. The success of continued steroid avoidance after kidney transplantation in the US. Am J Transplant. 2009;9:2768–2776. doi: 10.1111/j.1600-6143.2009.02838.x.
    1. Lodhi S, Lam K, Meier-Kriesche H. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant. 2011;12:1226–1135.
    1. Cole E, Johnston O, Rose C, Gill J. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am SocNephrol. 2008;3:814–821. doi: 10.2215/CJN.04681107.
    1. Vincenti F, Schena F, Paraskevas S, Hauser IA, Walker RG, Grinyo J. The randomized, multi-center study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008;8:307–316. doi: 10.1111/j.1600-6143.2007.02057.x.
    1. Woodle E, First M, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. Astellas Corticosteroid Withdrawal Study Group. A perspective, randomized, double-blind, placebo-controlled multi- center trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Annals of Surgery. 2008;248:564–577.
    1. Chadban S, Morris R, Hirsch H, Bunnapradist S, Arns W, Budde K. Immunosuppression in renal transplantation: some concepts for the modern era. Transplantation reviews. 2008;22:241–251. doi: 10.1016/j.trre.2008.05.003.
    1. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4:583–595. doi: 10.1046/j.1600-6143.2003.00372.x.
    1. Midtvedt K, Hjelmesaeth J, Hartmann A, Lund K, Paulsen D, Egeland T, Jenssen T. Insulin resistance after renal transplantation: the effect of steroid reduction and withdrawal. J Am SocNephrol. 2004;15:3233–3239.
    1. Ojo A, Hanson J, Wolfe R, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57:307–313. doi: 10.1046/j.1523-1755.2000.00816.x.
    1. Kasiske B, Snyder J, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–186. doi: 10.1034/j.1600-6143.2003.00010.x.
    1. Luan F, Steffick D, Gadegbeku C, Norman SP, Wolfe R, Ojo AO. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant. 2009;9:160–168.
    1. Rizzari M, Suszynski T, Gillingham K, Dunn TB, Ibrahim HN, Payne WD, Chinnakotla S, Finger EB, Sutherland DE, Kandaswamy R, Najarian JS, Pruett TL, Kukla A, Spong R, Matas AJ. Ten-year outcome after rapid discontinuation of Prednisone in adult primary kidney transplantation. Clin J Am SocNephrol. 2012;7:494–503. doi: 10.2215/CJN.08630811.
    1. TerMeulen C, van Riemsdijk I, Hené RJ, Christiaans MH, Borm GF, van Gelder T, Hilbrands LB, Weimar W, Hoitsma AJ. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a perspective randomized multi-center study. Am J Transplant. 2004;4:803–814. doi: 10.1111/j.1600-6143.2004.00419.x.
    1. Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, Margreiter R, Capdevilla L, Lang P, Vialtel P, Ortuño-Mirete J, Charpentier B, Legendre C, Sanchez-Plumed J, Oppenheimer F, Kessler M. CARMEN Study Group. Corticosteroid-free immunosuppression with tacrolimus, mycophenolatemofetil and daclizumab induction in renal transplantation. Transplantation. 2005;79:807–814. doi: 10.1097/01.TP.0000154915.20524.0A.
    1. Chapman J, O’Connell P, Nankivell B. Chronic renal allograft dysfunction. J Am SocNephrol. 2005;16:3015–3026.
    1. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N. DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international, randomized trial comparing -glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506–1514. doi: 10.1111/j.1600-6143.2007.01749.x.
    1. Webster A, Woodroff R, Taylor R, Chapman J, Craig J. Tacrolimus versus cyclosporine as primary immunosuppression for kidney transplant recipients; meta-analysis and meta-regression of randomized trial data. Br Med J. 2005;331:810–817. doi: 10.1136/.
    1. Balbontin F, Kiberd B, Fraser A, Kiberd M, Lawen J. Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant. Clin Transplant. 2005;19:225–229. doi: 10.1111/j.1399-0012.2005.00325.x.
    1. Sinclair NR. for the Canadian Multicenter Transplant Study Group. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. Can Med Assoc J. 1992;147:645–657.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren